Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Fuji
Boehringer Ingelheim
Federal Trade Commission
Medtronic
Colorcon
McKesson
Novartis
McKinsey
Cipla

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,545,644

« Back to Dashboard

Which drugs does patent 5,545,644 protect, and when does it expire?

Patent 5,545,644 protects RELPAX and is included in one NDA.

This patent has ninety-four patent family members in thirty-six countries.
Summary for Patent: 5,545,644
Title: Indole derivatives
Abstract:Compounds of the formula ##STR1## wherein n is 0, 1, or 2; X is hydrogen, chlorine, bromine or iodine; R.sub.1 is hydrogen; R.sub.3 is selected from hydrogen and C.sub.1 to C.sub.6 linear or branched alkyl; and R.sub.2 is as defined in the specification and the pharmaceutically acceptable salts thereof are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators. A process for forming indoles by transition metal catalyzed cyclization of a dihalogenated intermediate is also disclosed.
Inventor(s): Macor; John E. (New York, NY), Wythes; Martin J. (New York, NY)
Assignee: Pfizer Inc. (New York, NY)
Application Number:08/466,644
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 5,545,644

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF MIGRAINE WITH OR WITHOUT AURA ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF MIGRAINE WITH OR WITHOUT AURA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,545,644

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,559,129 Indole derivatives ➤ Subscribe
5,559,246 Indole derivatives ➤ Subscribe
5,607,951 Indole derivatives ➤ Subscribe
5,578,612 Indole derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,545,644

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 486 ➤ Subscribe
African Regional IP Organization (ARIPO) 9400633 ➤ Subscribe
Austria 157361 ➤ Subscribe
Austria 222492 ➤ Subscribe
Australia 6436094 ➤ Subscribe
Australia 651637 ➤ Subscribe
Australia 689469 ➤ Subscribe
Australia 8950491 ➤ Subscribe
Bulgaria 100093 ➤ Subscribe
Bulgaria 61898 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Citi
Federal Trade Commission
Moodys
Chubb
Colorcon
Cerilliant
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot